Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

gastrointestinal therapeutics

EU flag

EMA defends Humira redaction policy from transparency criticism

Regulator says spirit of trial transparency intact after its handling of AbbVie reports

- PMLiVE

Takeda’s ‘oral Velcade’ clears first phase III hurdle

Ixazomib shows early stage promise for myeloma

- PMLiVE

Imbruvica gets FDA OK for rare lymphoma

Cancer drug available in US to treat Waldenström's macroglobulinaemia          

- PMLiVE

FDA approves AbbVie’s Duopa in advanced Parkinson’s

Drug is administered into the stomach via a tube

- PMLiVE

Xarelto gets new atrial fibrillation label in Europe

First oral anticoagulant to gain EU approval in indication

- PMLiVE

Janssen will cover cost of unsuccessful hepatitis C treatment

NHS England will only have to pay for Olysio if patient clears virus

- PMLiVE

NICE backs new hepatitis C treatments

But Sovaldi faces funding delay and Olysio not backed in all indications

- PMLiVE

EC clears AbbVie’s oral hepatitis C regimen

Viekirax and Exviera offer competition to Gilead’s Sovaldi

- PMLiVE

NICE set to dismiss Millennium’s Crohn’s drug Entyvio

Body cites uncertain evidence and unlikely value for the NHS

- PMLiVE

Janssen partners with Isis on stomach conditions

Will develop treatments that target RNA in people with autoimmune disorders

- PMLiVE

Janssen and Gilead extend HIV collaboration

Will develop single tablet regimen that combines Prezista, Tybost, emtricitabine and tenofovir alafenamide

- PMLiVE

Sovaldi dropped by Express Scripts in favour of Viekira Pak

Pharmacy benefits organisation ramps up US pricing pressure on Gilead

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links